Retatrutide remains under scientific investigation
So for the moment, retatrutide is the exciting newcomer on the horizon, while semaglutide and tirzepatide are the current champions in practice
Comparatively, 32,336 GLP-1 receptor agonists and 96,212 SGLT-2 inhibitor users were followed for a median of 1.2 and 1.2 years, respectively
Gabriel Bsteh: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene/BMS, Novartis, Roche, Sanofi-Genzyme and Teva
The review concluded that where hair loss occurs, it is most plausibly explained by the rapid weight loss these drugs produce, which can trigger a temporary shedding condition called telogen effluvium, rather than by the medicine damaging the follicle directly